Metastatic Triple Negative Breast Cancer: Current Treatment Trends
Treatment of metastatic triple negative breast cancer has evolved rapidly in recent years. Traditional chemotherapy has been the mainstay, but the emergence of immunotherapy and targeted treatments has changed the therapeutic landscape. Immunotherapies, particularly immune checkpoint inhibitors, have demonstrated significant efficacy in subsets of patients with PD-L1 positive tumors, improving survival outcomes and quality of life.
Combination therapies are gaining prominence. For example, pairing chemotherapy with checkpoint inhibitors or PARP inhibitors has shown enhanced antitumor activity. PARP inhibitors, particularly for patients with BRCA mutations, exploit DNA repair deficiencies in tumor cells, leading to targeted cytotoxicity. Antibody-drug conjugates (ADCs) are also emerging as a potent therapeutic option, delivering cytotoxic agents directly to cancer cells while sparing healthy tissues.
Biomarker-driven treatment is increasingly important. PD-L1 expression, BRCA mutation status, and tumor-infiltrating lymphocytes (TILs) guide therapy selection, ensuring patients receive the most effective treatments with minimal side effects. Additionally, oral therapies and novel drug delivery systems are improving patient convenience and compliance.
While these trends are promising, challenges remain, including therapy resistance, disease heterogeneity, and management of adverse events. Nonetheless, the mTNBC treatment landscape continues to advance, emphasizing precision medicine and individualized care strategies.